Lexeo Therapeutics, Inc.: valuation

LXEONASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$2.96

November 20, 2026Market cap $245M

What Ploutos Investor adds for Lexeo Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 4 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Valuation today

What the market pays for the company's earnings, cash flow, book value and revenue at $2.96 (November 20, 2026), beside the median of its past fiscal years.

Today's P/B (1.1) is 62% below the median of the chart's 3 years (3.0).

EV / EBIT
–
EV / Revenue
–
Earnings yield
–
FCF yield
–
Market cap
$245M
enterprise value $26M
  • 2025
    P/E–
  • 2024
    P/E–
  • 2023
    P/E–

Each multiple at the closing price of the fiscal year's last trading day and the same year's figures. A year with a loss or negative free cash flow has no P/E or P/FCF.

Valuation against its own past

LXEO's P/E, P/FCF and P/B at each year-end price, from 2023 to 2023, 1 more fiscal year

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 4 fiscal years.

DCF calculator

What is Lexeo Therapeutics worth on your own assumptions?

The DCF calculator opens with the company's figures already filled in from its filings. You set how fast its cash flow grows and the return you ask for, and see the value those assumptions give.

Free cash flow, 12 months
-$88M
Net cash
$219M
Shares
82.79M
FCF, 5-year average a year
–
Revenue, 5-year average a year
–
Price
$2.96

The full analysis

What do Lexeo Therapeutics's filings show?

The multiples say what the market pays for Lexeo Therapeutics. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about LXEO's valuation

Didn't find what you were looking for?

Ask us
How do I work out what LXEO is worth?

With the DCF calculator: it opens with Lexeo Therapeutics's figures from its filings, you enter your assumptions for growth and the return you ask for, and see the value they give. The company pages give no price target of their own. A full analysis gives a fair-value range, which is an estimate, not a target.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. The estimated fair value, where shown, is our estimate, labelled as one: not a fact, not a score and not a recommendation to buy or sell.